Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 9/20 | 0.80 |
| ▸ | MMP2 | P08253 | 10/20 | 0.68 |
| ▸ | MMP13 | P45452 | 7/20 | 0.68 |
| ▸ | MMP14 | P50281 | 3/20 | 0.68 |
| ▸ | MMP7 | P09237 | 2/20 | 0.68 |
| ▸ | MMP12 | P39900 | 1/20 | 0.68 |
| ▸ | MMP3 | P08254 | 2/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13314510 | 1.00 | ADAMTS4 (0.80) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL3609279 | 0.89 | ADAMTS4 (0.63) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL12247612 | 0.89 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL12684680 | 0.89 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL1658546 | 0.89 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL3612773 | 0.84 | ADAMTS4 (0.80) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL8286012 | 0.84 | ADAMTS4 (0.80) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL20124798 | 0.81 | ADAMTS4 (0.86) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL12684636 | 0.81 | ADAMTS4 (0.73) | ADAMTS4MMP2MMP13MMP14MMP7 | |
| SCHEMBL3618624 | 0.81 | MMP2 (1.00) | ADAMTS4MMP2MMP13MMP14MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | claimed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | claimed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | WYETH (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1692124-B1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-7420001-B2 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1692124-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | Wyeth (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005061477-A1 | BIARYL SULFONAMIDES AS MMP INHIBITORS | WYETH (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | ADAMTS4 63/4885MMP2 106/4885MMP13 257/4885 |
| US-20100137298-A1 | Biaryl Sulfonamides and Methods for Using Same | STS, MMP3, AADAC | ADAMTS4 113/4885MMP2 5/4885MMP13 13/4885 |
| US-20050143422-A1 | Biaryl sulfonamides and methods for using same | STS, MMP3, AADAC | ADAMTS4 113/4885MMP2 5/4885MMP13 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.